Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists’ Clinical Management Decisions

May 2017 | Volume 16 | Issue 5 | Original Article | 428 | Copyright © May 2017

Aaron S. Farberg MD,a Alex M. Glazer MD,b Richard White MS,c and Darrell S. Rigel MD MSd

aDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY bNational Society for Cutaneous Medicine, New York, NY cIris Interactive System, Cody, WY dDepartment of Dermatology, NYU School of Medicine, New York, NY


  1. Coit DG, Thompson JA, Algazi A, et al. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(4):450-73. 
  2. Bichakjian CK, Halpern AC, Johnson TM, et al.Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011;65(5):1032-47. 
  3. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206. 
  4. Rigel DS, Mrinalini R, Yoo J, et al. Impact of guidance from a computer-aided multispectral digital skin lesion analysis device on suspicion to biopsy lesions clinically suggestive of melanoma. Arch Dermatol. 2012;148(4):541-543. 
  5. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175-83. 
  6. Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780-5 e783. 
  7. Lawson DH, Russell MC, Wilkinson J, et al. Continued evaluation of a 31- gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM). J Clin Oncol. 2015; 33 (suppl; abstr 9066). 
  8. Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high risk cutaneous melanoma tumors is improved when combining the online AJCC melanoma patient outcome prediction tool with a 31-gene expression profile–based classification. J Am Acad Dermatol. In Press. 
  9. Ribero S, Longo C, Glass D, Nathan P, Bataille V. What is New in Melanoma Genetics and Treatment? Dermatology. 2016;232(3):259-64. 
  10. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452-2459. 
  11. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609. 
  12. Morton DL, Thompson JF, Alistair JC, et al. Final trial report of sentinel-node biopsy versus observation in melanoma. N Engl J Med. 2014;370:599-609. 
  13. Cordeiro E, Gervais MK, Shah PS, et al. Sentinel lymph node biopsy in thin cutaneous melanoma: A systematic review and meta-analysis. Ann Surg Oncol. 2016;23(13):4178-88. 
  14. Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32(9):1599-1604. 


Alex M. Glazer MD alexglazer@gmail.com